Literature DB >> 26770323

Expression of KAP1 in epithelial ovarian cancer and its correlation with drug-resistance.

Mingqiu Hu1, Xin Fu2, Yanfen Cui3, Shilei Xu3, Yue Xu3, Qiuping Dong3, Lu Sun2.   

Abstract

KAP1 is a universal corepressor for Kruppel-associated box zinc finger proteins. In this study, expression level of KAP1 and its association with drug resistance and expression of P-gp and BCRP in epithelial ovarian cancer were investigated. Immunohistological staining of KAP1 in cancer and matched paraneoplastic tissues was evaluated in 242 patients with epithelial ovarian cancer. Immunohistological staining of P-gp and BCRP were also evaluated, and the associations with the expression of KAP1 in epithelial ovarian cancer were investigated. MTT assay for cell proliferation and clonogenic survival assay were applied to determine the effect of KAP1 on the sensitivity of DDP, through up-regulating the level of KAP1 expression of SKOV3 using KAP1 plasmid and down-regulating the level of KAP1 expression of SKOV3/DDP using siRNA. The results demonstrated that the expression levels of KAP1 in cancer tissues were higher than matched paraneoplastic tissues (t = 21.39, P<0.001). The patients with higher KAP1 expression often had drug resistance, and the level of KAP1 expression was positively correlated with the expression of P-gp and BCRP (P = 0.07 and P<0.001 respectively). Up-regulated the expression of KAP1 in SKOV3 cell line induced the up-regulated expression of BCRP and P-gp, increasing the resistance of chemotherapeutic drug, and down-regulated the expression of KAP1 got opposite effects. KAP1 expression correlated with aggressive clinical features in ovarian cancer, maybe through regulating the expression of P-gp and BCRP.

Entities:  

Keywords:  BCRP; KAP1; Ovarian cancer; P-gp; drug resistance

Year:  2015        PMID: 26770323      PMCID: PMC4694223     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  36 in total

1.  [Clinicopathological features associated with EGFR gene mutation in non-small cell lung cancer patients].

Authors:  Jianya Zhou; Weifang Mo; Jing Zhao; Jing Zheng; Wei Ding; Jianying Zhou
Journal:  Zhonghua Yi Xue Za Zhi       Date:  2014-08-13

2.  Purification, crystallization and preliminary crystallographic analysis of protein MJ1225 from Methanocaldococcus jannaschii, a putative archaeal homologue of gamma-AMPK.

Authors:  Inmaculada Gómez García; Danel Kortázar; Iker Oyenarte; José María Mato; María Luz Martínez-Chantar; Luis Alfonso Martínez-Cruz
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2009-07-30

3.  Mechanisms of multidrug resistance in cancer.

Authors:  Jean-Pierre Gillet; Michael M Gottesman
Journal:  Methods Mol Biol       Date:  2010

4.  TRIM29 functions as a tumor suppressor in nontumorigenic breast cells and invasive ER+ breast cancer.

Authors:  Jin Liu; Bryan Welm; Ken M Boucher; Mark T W Ebbert; Philip S Bernard
Journal:  Am J Pathol       Date:  2011-12-02       Impact factor: 4.307

5.  Predictive markers of chemoresistance in advanced stages epithelial ovarian carcinoma.

Authors:  Claire Bonneau; Roman Rouzier; Caroline Geyl; Annie Cortez; Mathieu Castela; Raphael Lis; Emile Daraï; Cyril Touboul
Journal:  Gynecol Oncol       Date:  2014-11-01       Impact factor: 5.482

Review 6.  Three decades of P-gp inhibitors: skimming through several generations and scaffolds.

Authors:  A Palmeira; E Sousa; M H Vasconcelos; M M Pinto
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

Review 7.  Multidrug resistance through the spectacle of P-glycoprotein.

Authors:  Katalin Goda; Zsolt Bacsó; Gábor Szabó
Journal:  Curr Cancer Drug Targets       Date:  2009-05       Impact factor: 3.428

8.  Site-specific gene expression profiles and novel molecular prognostic factors in patients with lower gastrointestinal adenocarcinoma diffusely metastatic to liver or peritoneum.

Authors:  Sheelu Varghese; Monika Burness; Hui Xu; Tatiana Beresnev; James Pingpank; H Richard Alexander
Journal:  Ann Surg Oncol       Date:  2007-09-25       Impact factor: 5.344

9.  The matrix metalloproteinase/tissue inhibitor of matrix metalloproteinase profile in colorectal polyp cancers.

Authors:  Natalie Jeffery; Mairi H McLean; Emad M El-Omar; Graeme I Murray
Journal:  Histopathology       Date:  2009-06       Impact factor: 5.087

Review 10.  TWIST and ovarian cancer stem cells: implications for chemoresistance and metastasis.

Authors:  Sudhakar V Nuti; Gil Mor; Peiyao Li; Gang Yin
Journal:  Oncotarget       Date:  2014-09-15
View more
  9 in total

1.  The SETDB1-TRIM28 Complex Suppresses Antitumor Immunity.

Authors:  Jianhuang Lin; Dajiang Guo; Heng Liu; Wei Zhou; Chen Wang; Iris Müller; Andrew V Kossenkov; Ronny Drapkin; Benjamin G Bitler; Kristian Helin; Rugang Zhang
Journal:  Cancer Immunol Res       Date:  2021-12       Impact factor: 12.020

2.  Disruption of RING and PHD Domains of TRIM28 Evokes Differentiation in Human iPSCs.

Authors:  Sylwia Mazurek; Urszula Oleksiewicz; Patrycja Czerwińska; Joanna Wróblewska; Marta Klimczak; Maciej Wiznerowicz
Journal:  Cells       Date:  2021-07-29       Impact factor: 6.600

3.  Negative Regulation of BOK Expression by Recruitment of TRIM28 to Regulatory Elements in Its 3' Untranslated Region.

Authors:  Yuniel Fernandez-Marrero; Daniel Bachmann; Emanuel Lauber; Thomas Kaufmann
Journal:  iScience       Date:  2018-11-10

4.  Inhibition of HIV-1 gene transcription by KAP1 in myeloid lineage.

Authors:  Amina Ait-Ammar; Maxime Bellefroid; Fadoua Daouad; Valérie Martinelli; Jeanne Van Assche; Clémentine Wallet; Anthony Rodari; Marco De Rovere; Birthe Fahrenkrog; Christian Schwartz; Carine Van Lint; Virginie Gautier; Olivier Rohr
Journal:  Sci Rep       Date:  2021-01-29       Impact factor: 4.379

5.  Knockdown of KRAB domain-associated protein 1 suppresses the proliferation, migration and invasion of thyroid cancer cells by regulating P68/DEAD box protein 5.

Authors:  Hai Lan; Congyao Lin; Hongyin Yuan
Journal:  Bioengineered       Date:  2022-05       Impact factor: 6.832

6.  Downregulation of TRIM28 inhibits growth and increases apoptosis of nude mice with non‑small cell lung cancer xenografts.

Authors:  Lei Liu; Lei Zhang; Jianping Wang; Xuerong Zhao; Qian Xu; Yanjie Lu; Yanzhen Zuo; Long Chen; Jia Du; Yali Lian; Qin Zhang
Journal:  Mol Med Rep       Date:  2017-11-03       Impact factor: 2.952

Review 7.  The complexity of TRIM28 contribution to cancer.

Authors:  Patrycja Czerwińska; Sylwia Mazurek; Maciej Wiznerowicz
Journal:  J Biomed Sci       Date:  2017-08-29       Impact factor: 8.410

8.  TRIM28 is overexpressed in glioma and associated with tumor progression.

Authors:  Chunhai Su; Hui Li; Wenbo Gao
Journal:  Onco Targets Ther       Date:  2018-10-10       Impact factor: 4.147

9.  TRIM28 inhibits alternative lengthening of telomere phenotypes by protecting SETDB1 from degradation.

Authors:  Chuanle Wang; Zhou Songyang; Yan Huang
Journal:  Cell Biosci       Date:  2021-07-30       Impact factor: 7.133

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.